Tuesday

4th Oct 2022

EU silent on US buying up world's remdesivir supplies

The European Commission on Wednesday (1 July) refused to speak out against the US decision to buy up most of the world's stock of remdesivir.

The drug, manufactured by the US-based biopharmaceutical company Gilead, has been proven to work against Covid-19.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Two of the most senior European Commission officials, vice-presidents Margaritis Schinas and Valdis Dombrovskis, declined to respond to questions on the US move during a press conference on Wednesday.

Instead, the European Commission's official spokesperson services in an email sent later in the day announced it had taken "note of the announcement made yesterday regarding doses available for the US."

The tiptoeing may be due to broader efforts by the Commission to negotiate with Gilead for reserve doses of remdesivir for EU member states.

"Given the confidentiality of these discussions, no details can be given at this stage," said European commission spokesperson, Stefan de Keersmaecker, in an emailed statement.

But with the US buying up three months of stocks, leaving Europe and most the world without, the commission's strategy to secure the drug is likely to pose some tricky questions.

The Trump administration bought more than 500,000 doses, spanning all of Gilead's production for July and throughout most of autumn.

Similar tactics by the Trump administration in March to acquire the exclusive rights to a vaccine being developed by CureVac, a German firm, were roundly condemned.

In May, the French government expressed outrage after the CEO of the French pharmaceutical giant Sanofi said the US would get first doses on any Covid-19 vaccine.

Meanwhile, Germany on Wednesday told Reuters news agency it had secured sufficient supplies of remdesivir.

"The federal government has early on secured remdesivir for the treatment of coronavirus patients. Currently, there are still sufficient reserves," Germany's health ministry told Reuters in a written statement.

The Amsterdam-based European Medicines Agency (EMA) had only last week recommended granting a conditional marketing authorisation for remdesivir.

The drug is the first and so far the only Covid-19 treatment recommended for EU authorisation.

"As of 15 June, EMA has been in contact with developers of 132 potential Covid-19 therapeutics and 34 potential vaccines," the EMA said in an email.

For its part, the commission says their decision to speed up the process to grant a marketing authorisation for remdesivir in the coming days, is a demonstration of their commitment to ensure that scientifically proven effective treatments for Covid-19 are available to EU citizens.

Analysis

Waking up after corona. How will the world look?

Many people hoped that after corona we would wake up in a friendlier world. Unfortunately, the opposite seems to be the case. A cocktail of several fears is fuelling the already existing trend of polarisation, worldwide.

Investigation

EU taxpayers in the dark on US corona-drug deal

The EU recently signed a huge contract for a US anti-corona drug which, the WHO says, might not work, but there's little transparency on how the deal was made.

Deregulation of new GMO crops: science or business?

Academics and biotech research organisations with corporate interests have been leading the lobby campaign to deregulate new genomic techniques in the EU — using 'climate-friendly' and 'science-based' narratives, according to a report.

Netherlands tops EU social safety net for the poor

The Netherlands is the only EU state where the minimum income is above the poverty line. A minimum income is not a wage but rather a social safety net to ensure people do not end up destitute.

News in Brief

  1. Czechs warn joint-nationality citizens in Russia on mobilisation
  2. Greece to unveil proposal for capping EU gas prices
  3. Four dead, 29 missing, after dinghy found off Canary Islands
  4. Orbán: German €200bn shield is start of 'cannibalism in EU'
  5. Lithuania expels top Russian diplomat
  6. Poland insists on German WW2 reparations
  7. Russia halts gas supplies to Italy
  8. Bulgaria risks hung parliament after inconclusive vote

Stakeholders' Highlights

  1. The European Association for Storage of EnergyRegister for the Energy Storage Global Conference, held in Brussels on 11-13 Oct.
  2. EFBWW – EFBH – FETBBA lot more needs to be done to better protect construction workers from asbestos
  3. European Committee of the RegionsThe 20th edition of EURegionsWeek is ready to take off. Save your spot in Brussels.
  4. UNESDA - Soft Drinks EuropeCall for EU action – SMEs in the beverage industry call for fairer access to recycled material
  5. Nordic Council of MinistersNordic prime ministers: “We will deepen co-operation on defence”
  6. EFBWW – EFBH – FETBBConstruction workers can check wages and working conditions in 36 countries

Latest News

  1. Last-minute legal changes to Bosnian election law stir controversy
  2. EU wants probe into alleged Nagorno-Karabakh war crimes
  3. EU officials were warned of risk over issuing financial warning
  4. EU debates national energy plans amid calls for more coordination
  5. What Modi and Putin’s ‘unbreakable friendship’ means for the EU
  6. EU leaders have until Friday for refugee resettlement pledges
  7. Cities and regions stand with citizens and SMEs ahead of difficult winter
  8. Editor's weekly digest: A week of leaks

Join EUobserver

Support quality EU news

Join us